<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625569</url>
  </required_header>
  <id_info>
    <org_study_id>Naload</org_study_id>
    <nct_id>NCT04625569</nct_id>
  </id_info>
  <brief_title>Genetic of Response to Acute Saline Load Test in Hypertension (Naload)</brief_title>
  <acronym>Naload</acronym>
  <official_title>Role of Genetic Determinants in the Response to Acute Saline Load Testing in Patients With Essential Hypertension (Naload)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NHP referred to our outpatient clinic will be enrolled (150 newly recruited) in acute saline&#xD;
      test for phenotype characterisation of PNat relationship(7). For each patient we will collect&#xD;
      urine and blood samples for standard clinical biochemistry, including electrolytes,&#xD;
      creatinine, EO, aldosterone, plasma renin activity, urinary uromodulin (ELISA), urinary and&#xD;
      serum uric acid and blood samples for genetic test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute salt load test: after the equilibration period and achievement of a steady state, a&#xD;
      constant-rate i.v. infusion of 2 L of 0.9% NaCl was carried out in 2 hours. BP (mean of 3&#xD;
      measurements taken 3 minutes apart) was measured every 30 minutes during the 2 hours of&#xD;
      loading and 3 times at 3-min intervals at the end of the infusion. These last 3 BP values&#xD;
      were averaged and used in the analysis.&#xD;
&#xD;
      The results of these tests will be added to an already collected database of salt load test&#xD;
      collected in the previous studies (already published)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">November 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DMBP120</measure>
    <time_frame>120 min</time_frame>
    <description>Blood pressure variation at the end of infusion</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypertension,Essential</condition>
  <condition>Salt; Excess</condition>
  <condition>Genetic Hypertension</condition>
  <condition>Genetic Predisposition to Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and urinary sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We enrolled newly discovered, never treated, mild hypertensive male patients in the&#xD;
        'Outpatient Clinic for Hypertension' of San Raffaele Hospital, Milan (Italy)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 to 65years;&#xD;
&#xD;
          -  body mass index (BMI) &lt;30 kg/m2;&#xD;
&#xD;
          -  Na intake, evaluated as urinary Na excretion of &lt;300 mEq/24 hours; .office systolic BP&#xD;
             (SBP) &gt;140 mm Hg and diastolic BP (DBP) &gt;90 mm Hg in 3 consecutive visits to their&#xD;
             family doctors.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Female patients&#xD;
&#xD;
          -  history of myocardial infarction,&#xD;
&#xD;
          -  stroke,&#xD;
&#xD;
          -  congestive heart failure,&#xD;
&#xD;
          -  liver disease, secondary cause of hypertension,&#xD;
&#xD;
          -  diabetes,&#xD;
&#xD;
          -  severe hypertension (&gt;160/110 mm Hg),&#xD;
&#xD;
          -  abuse of drugs or alcohol, .creatinine clearance &lt; 80 mL/m.&#xD;
&#xD;
        Secondary forms of hypertension (e.g. primary aldosteronism) were ruled out with specific&#xD;
        investigations when deemed appropriate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiara Lanzani, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiara Lanzani, doctor</last_name>
    <phone>0206433891</phone>
    <email>lanzani.chiara@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cinzia Scotti, secretary</last_name>
    <phone>0226435330</phone>
    <email>scotti.cinzia@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Lanzani, MD</last_name>
      <phone>+390226433891</phone>
      <email>lanzani.chiara@hsr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, Citterio L, Demaretz S, Trevisani F, Ristagno G, Glaudemans B, Laghmani K, Dell'Antonio G; SKIPOGH team, Loffing J, Rastaldi MP, Manunta P, Devuyst O, Rampoldi L. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med. 2013 Dec;19(12):1655-60. doi: 10.1038/nm.3384. Epub 2013 Nov 3.</citation>
    <PMID>24185693</PMID>
  </reference>
  <reference>
    <citation>Citterio L, Delli Carpini S, Lupoli S, Brioni E, Simonini M, Fontana S, Zagato L, Messaggio E, Barlassina C, Cusi D, Manunta P, Lanzani C. Klotho Gene in Human Salt-Sensitive Hypertension. Clin J Am Soc Nephrol. 2020 Mar 6;15(3):375-383. doi: 10.2215/CJN.08620719. Epub 2020 Jan 28.</citation>
    <PMID>31992575</PMID>
  </reference>
  <reference>
    <citation>Lanzani C, Gatti G, Citterio L, Messaggio E, Delli Carpini S, Simonini M, Casamassima N, Zagato L, Brioni E, Hamlyn JM, Manunta P. Lanosterol Synthase Gene Polymorphisms and Changes in Endogenous Ouabain in the Response to Low Sodium Intake. Hypertension. 2016 Feb;67(2):342-8. doi: 10.1161/HYPERTENSIONAHA.115.06415. Epub 2015 Dec 14.</citation>
    <PMID>26667413</PMID>
  </reference>
  <reference>
    <citation>Citterio L, Ferrandi M, Delli Carpini S, Simonini M, Kuznetsova T, Molinari I, Dell' Antonio G, Lanzani C, Merlino L, Brioni E, Staessen JA, Bianchi G, Manunta P. cGMP-dependent protein kinase 1 polymorphisms underlie renal sodium handling impairment. Hypertension. 2013 Dec;62(6):1027-33. doi: 10.1161/HYPERTENSIONAHA.113.01628. Epub 2013 Sep 23.</citation>
    <PMID>24060892</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Raffaele</investigator_affiliation>
    <investigator_full_name>Chiara Lanzani</investigator_full_name>
    <investigator_title>Medical doctor in nephrology unit, nephrologist</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>salt sensitivity</keyword>
  <keyword>genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

